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Abstract: Amifostine is added to chemoradiation regimens in the treatment of many 
cancers on the basis that, by reducing the metabolic rate, it protects normal cells from toxic 
effects of therapy. We tested this hypothesis by measuring the metabolic rate (by gas 
exchange) over 255 min in 6 healthy subjects, at two doses (500 mg and 1000 mg) of 
amifostine infused over 15 min at the start of the protocol. We also assessed the ventilatory 
response to six 1 min exposures to isocapnic hypoxia mid-protocol. There was no change 
in metabolic rate with amifostine as measured by oxygen uptake (p = 0.113). However in 
carbon dioxide output and respiratory quotient, we detected a small decline over time in 
control and drug protocols, consistent with a gradual change from carbohydrate to fat 
metabolism over the course of the relatively long study protocol. A novel result was that 
amifostine (1000 mg) increased the mean ± SD acute hypoxic ventilatory response from 
12.4 ± 5.1 L/min to 20.3 ± 11.9 L/min (p = 0.045). In conclusion, any cellular protective 
effects of amifostine are unlikely due to metabolic effects. The stimulatory effect on 
hypoxic ventilatory responses may be due to increased levels of hypoxia inducible factor, 
either peripherally in the carotid body, or centrally in the brain. 
Keywords: hypoxia; hypercapnia; ventilation; ventilatory control; chemoreflexes; 
metabolism; gas exchange; hypoxia-inducible factor 
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1. Introduction 
The drug amifostine (whose active metabolite is 2-((aminopropyl)amino)ethanethiol) is added to the 
chemoradiation regimens in the treatment of several cancers to protect normal healthy cells from the 
toxic effects of treatment and to reduce side effects such as xerostomia. Amifostine increases rates of 
response in several types of tumour, including tumours of the uterine cervix, oesophagus, rectum, 
small-cell lung cancers, and locally advanced carcinomas of the head and neck [1]. The precise mode 
of action has not been fully elucidated. One possibility is that its conversion to a disulfide enables 
subsequent scavenging of free radicals, thus protecting the normal cell against DNA and cell 
membrane damage by chemo- radiotherapy [2]. Notably, metabolic conversion of amifostine to 
WR33278 results in reduced oxygen consumption of healthy tissue [3]. This observation was based on 
the finding that venous haemoglobin saturation and PO2 increased with amifostine administration in 
patients. However, this observation was subsequently questioned by Koukourakis et al. (2004) [4], 
who reported a biphasic response. Although haemoglobin saturation and PO2 rose slightly at 30 min 
after administration, at 60 min there was a more profound fall in these measures. No previous study 
has measured the effect of amifostine on metabolic rate (e.g., by gas exchange) in humans. 
Furthermore amifostine may, directly or indirectly, upregulate the expression of a variety of 
proteins, including HIF-1α, involved in the process of DNA repair and apoptosis inhibition [4,5]. It has 
been reported that HIF-1α is involved in carotid body transduction of hypoxia, such that increased 
levels (or increased stability of HIF-1α) augments the ventilatory hypoxic response [6,7]. Therefore,  
if amifostine increases HIF-1α levels in the carotid body, it might also have the effect of augmenting 
the ventilatory hypoxic response. 
In relation to the drug amifostine, these two lines of investigation are contradictory. If some of the 
cancer therapeutic literature is correct and amifostine reduces whole-body metabolic rate, then we 
might expect it to reduce the magnitude of hypoxic ventilatory response. This is for the reason that,  
in conditions of increased metabolic rate such as exercise, hypoxic ventilatory response is consistently 
increased [8,9]. However, if the line of enquiry relating to HIF-1α and the carotid body is correct,  
we would expect the hypoxic ventilatory response to be increased. It is important in the field of cancer 
therapeutics that the actions of drugs like amifostine is known. It is also suggested that manipulation  
of metabolic rate may be an important aspect of outcomes in anaesthesia and intensive care [10].  
We therefore wished to test two hypotheses. First, we wished to establish if (as suggested by the 
cancer therapeutic literature) metabolic rate is in fact reduced by amifostine. This would be an 
important and novel finding as we are not aware of any drug or therapy that reduces basal metabolic 
rate in humans. Second, we wished to assess by direct measurement whether hypoxic ventilatory 
response is increased or reduced by amifostine. 
2. Experimental Section 
After Oxford Research Ethics Committee approval (06/Q1606/117) and written informed consent,  
6 healthy subjects (3 females) were studied; their mean ± SD age was 24.8 ± 8.7 yrs, weight 73.0 ± 7.1 kg, 
height 174 ± 5 cm. Metabolic gas exchange was assessed over a 255 min period of continuous air 
breathing, against a background infusion of: (a) 500 mg amifostine; (b) 1000 mg amifostine; or (c) 
control saline, in random order (sealed envelope selection, in advance), on different days. Female 
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subjects were studied in the same phase of their menstrual cycle. Amifostine was administered over  
15 min and at doses in accordance with clinical protocols [4,11]. The assessment of acute hypoxic 
response was conducted mid-way during this protocol (time = 100 min) over a ~20 min period.  
The end-tidal gas profile was: an initial 10 min period of air breathing (end tidal partial pressure 
carbon dioxide, PETCO2 40 Torr, end tidal partial pressure oxygen PETO2 100 Torr), followed by six  
1 min steps of isocapnic hypoxia (PETO2 50 Torr) alternating with 1 min recovery (PETCO2 40 Torr, 
PETO2 100 Torr). 
Infusion of amifostine was conducted into a forearm vein at the rate of 10 mL/h. Amifostine 
(Sigma-Aldrich, Poole, UK) was dissolved in saline to achieve a concentration of 20 or 40 mg/mL for 
the 500 mg and 1000 mg doses, respectively. Because amifostine has been reported to cause nausea 
and vomiting, subjects were pre-treated with 8 mg of intravenous ondansetron and 10 mg of intravenous 
metoclopramide (which were also administered in control protocols). 
The control of end-tidal gases in all protocols was achieved using a computer-controlled gas-mixing 
system, described in detail elsewhere [12,13]. Briefly, time profiles for inspiratory PCO2 and PO2 that 
were likely to produce the desired sequences in PETCO2 and PETO2 were predicted and imposed during 
the experiment. Actual PETCO2 and PETO2 values as measured by mass spectrometer were fed back into 
the computer breath-by-breath, compared with the desired values, and adjusted breath-by-breath using 
a system of gas cylinders controlled by fast-responding valves to force the PETCO2 and PETO2 towards 
the desired values. Subjects sat comfortably, breathing through a mouthpiece with their nose occluded. 
Respiratory volumes were recorded using a bi-directional turbine-measuring device. 
Heart rate and blood oxygen saturation were measured continuously and blood pressure was 
measured at regular intervals in all protocols. Blood samples were taken on every hour and analysed 
for erythropoietin (EPO) and vascular endothelial growth factor (VEGF) concentrations. 
Data were averaged over 30 s intervals and analyzed using our EXHALE program to determine O2 
consumption ( O2) and CO2 production ( CO2) at the mouth, as well as minute ventilation. The 
method has been described elsewhere [14,15], but briefly: the records of the CO2 and O2 composition 
at the mouth were time-aligned with that of respiratory flow, using the mass spectrometer delay time. 
Then, the flow values were adjusted for changes in viscosity due to changes in gas composition. Third, 
for each half breath, the respiratory flow profile was calibrated for volume. Fourth, for each gas, the 
difference between the amount breathed in and the amount breathed out was calculated, using an 
assumed expired temperature. This assumed expired temperature was then adjusted until it resulted in 
the net nitrogen exchange over the experimental period being equal to zero. 
Respiratory quotient (RQ) was then calculated as CO2/ O2. The mean of each 10 min period of 
mouth piece breathing was calculated to assess O2, CO2 and RQ. These values were available 
breath-by-breath but where results showed linear trends, any change in metabolic variables was 
calculated by subtracting the start-point average (the 10 min average of the first period of mouth piece 
breathing at t = 15) with the end-point average (the 10 min average of the last period of mouth piece 
breathing at t = 240). The 30 s periods before the onset of hypoxia and the highest response during the 
1 min period of hypoxia were used to calculate the acute hypoxic response, with each protocol 
provided multiple hypoxic periods. 
The study was powered to detect a difference in the main outcome measure (oxygen consumption) 
of 50 mL/min. Previous work [9] indicates that the standard deviation of this change in human subjects 
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is ~25 mL/min; Lehr’s formula thus estimates a sample size of 4 for 80% power at the 5% level, so 6 
subjects achieve at least this power [16]. 
Results were assessed using factorial analysis of variance (ANOVA), with factors being “subject”, 
“drug”, and (for metabolic data) “time” [17]. Post-hoc differences were assessed using t-tests. 
Significance was assumed when p < 0.05. 
3. Results 
Figure 1 (A–B) shows the gas input profile and ventilatory response for one example subject. Gas 
control was good with sharp steps into and out of hypoxia while PETCO2 was held suitably constant. 
Figure 1 (C–E) shows the resulting ventilatory responses. It appeared that amifostine, in increasing 
doses, increased the response to hypoxia and perhaps, at the highest dose, increased basal ventilation. 
Figure 1. Panels A and B: Gas input protocol for one example subject for the ~20 min 
period of measurement of hypoxic ventilatory response. Panel A, PETCO2; Panel B, PETO2 
profile. Panels C–E: Ventilatory responses for one example subject for the ~20 min period 
of measurement of hypoxic ventilatory response. Panel C, control; Panel D, with 500 mg 
amifostine; Panel E, with 1000 mg amifostine. 
 
Figure 2 shows the metabolic gas exchange data for all subjects combined. There appears to be a 
decline over time in CO2, but less so in O2, such that RQ declines over time. However, there does 
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not seem to be a pronounced drug effect. This was confirmed by data analysis. ANOVA for CO2 
indicated significant effects over “time” (p = 0.038), but not of “drug” (p = 0.532) or of the interactive 
term (“drug” * “time”, p = 0.935). However, the downward trend in O2 over time was not significant 
(p = 0.113), nor was there a significant “drug” effect (p = 0.765). Thus, the corresponding downward 
trend in RQ over time was significant (ANOVA; p = 0.001). Again, this reduction was not dependent 
on variation in “drug” (p = 0.677) or of the interactive term (p = 0.321). 
Figure 2. Mean ± SD for all subjects, of CO2 (Panel A), O2 (Panel B) and RQ over time 
for control (●), 500 mg amifostine (○) and 1000 mg amifostine () protocols. The “first 
period” represents the mean of values over the first 10 min of data collection (time = 15–25 
min) and the “last period” to the last 10 min of data collection (time = 240–255 min). 
 
Pharmaceuticals 2015, 8 191 
 
Table 1 shows the data for each individual and for the group as a whole. Amifostine did not have an 
effects on baseline ventilation (the “drug” effect in ANOVA NS, p = 0.402). However, the drug 
increased hypoxic ventilatory response (“drug” effect in ANOVA p = 0.016); post-hoc t-tests located 
this effect to the comparison of high-dose vs. control (p = 0.045) and to high-dose vs. low-dose  
(p = 0.027), but not to the comparison of low-dose amifostine vs. control (p = 0.491). 
Table 1. Effects of amifostine on basal minute ventilation and the acute hypoxic response 
(absolute values). Control, 500 mg and 1000 mg amifostine shown in columns, in order. 
Subject no. 
Baseline ventilation; mean (SD) (L/min)  Hypoxic ventilatory response; mean (SD) (L/min) 
Control 500 mg 1000 mg  control 500 mg 1000 mg 
1096 12.8 (1.9) 9.1 (0.6) 9.4 (1.4)  10.3 (2.8) 8.0 (2.8) 9.8 (2.6) 
1529 10.1 (0.7) 7.0 (0.5) 6.8 (1.5)  7.4 (0.5) 4.9 (1.0) 11.3 (1.7) 
1599 12.2 (1.6) 10.6 (0.5) 9.7 (0.8)  5.9 (0.8) 4.9 (3.4) 8.5 (2.0) 
1638 12.0 (0.9) 12.1 (3.4) 20.4 (0.9)  17.6 (3.8) 23.2 (3.0) 36.7 (4.0) 
1646 14.4 (1.4) 12.3 (0.6) 20.6 (2.7)  16.1 (5.2) 24.4 (3.3) 26.2 (1.8) 
1649 12.3 (1.8) 19.1 (1.9) 18.8 (3.1)  16.8 (2.0) 16.9 (1.9) 29.0 (5.0) 
Mean 12.3 11.7 14.3  12.4 13.7 20.3 
SD 1.4 4.1 6.3  5.1 9.0 11.9 
There was no significant alteration in VEGF plasma levels (mean 74.7 pg/mL) with ‘drug’ 
(ANOVA, p = 0.756) or “time” (ANOVA, p = 0.406). EPO concentrations (mean 7.1 pg/mL) also did 
not vary with “drug” (ANOVA, p = 0.430) or “time” (ANOVA, p = 0.920). 
Cardiovascular responses were assessed because amifostine can cause hypotension but there were 
no changes in heart rate or blood pressure with amifostine (data not shown) and all subjects were 
cardiovascularly stable throughout the protocols. 
4. Discussion 
We report the novel finding that high doses of amifostine markedly increased hypoxic ventilatory 
response. Furthermore, contrary to reports from the cancer therapeutic literature, we did not find 
significant influence of the drug on whole-body metabolic rate. 
In contrast to earlier suggestions that amifostine might reduce metabolic rate based on isolated 
tissue samples in microcalorimetry [18] or based on only indirect assessment venous blood gas levels [3], 
we found no reduction in CO2 or O2 (and thus, RQ) with amifostine in whole-body study. Instead, 
we report an incidental small decline in time in CO2 and RQ (19% and 7%, respectively) across all 
our protocols, including the control protocol. We ascribe this to the effect of starvation. The 
experimental period was rather long (255 min) and the RQ declined from a value of ~0.8 indicating 
carbohydrate metabolism to one of ~0.7 closer to fat metabolism (Figure 2). This is a well-known 
phenomenon in short-term starvation during both rest and exercise [14,19]. 
Our results in relation to hypoxic response are consistent with the notion that amifostine is thought 
to increase levels of (or to stabilise) hypoxia inducible factor (HIF), a transcription factor which binds 
to hypoxia response elements in the promoters of target genes. Yet, we did not find any increase in 
plasma VEGF or EPO, which might have been expected with HIF activation. However, some studies 
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report that VEGF can be suppressed by hypoxia and our hypoxic tests might have counteracted any 
tendency for VEGF plasma levels to increase as a result of amifostine infusion [20]. If amifostine 
stimulates HIF we might have expected to observe a rise in EPO. In retrospect this expectation may 
have been misplaced as amifostine in fact has a limited effect on plasma EPO levels or haemoglobin [21], 
i.e., its effects are probably confined to tissues rather than detectable systemically. Note that not  
all previous studies have reported a stimulation of amifostine on HIF: Dedieu et al. failed to find an 
effect [22], albeit their findings were confined to tumour cell lines. 
In vivo experiments with breast tumour cell lines show amifostine administration results in HIF1α 
induction and in rats results in increased HIF1α accumulation in normal tissue [4]. Though the exact 
cellular mechanism of oxygen sensing and signalling in the carotid body cells is not known, there is an 
increasing body of evidence implicating the involvement of HIF. Isolated carotid bodies of mice that 
are heterozygous for a knockout allele at the Hif1a locus show little increase in carotid sinus nerve 
activity in response to acute hypoxia. Hif1a+/− mice show impaired physiological responses to chronic 
hypoxia [23,24]. 
Based on this evidence, an upregulatory effect of amifostine on the HIF pathway in the carotid body 
could cause an increased ventilatory response to hypoxia, but the precise mechanism of how this is 
achieved within the carotid body is not known. In fact, carotid-chemodenervated rats can later develop 
ventilatory responses to sustained hypoxia, associated with upregulation of tyrosine hydroxylase in 
brainstem catecholaminergic neurones [25], suggesting that O2-sensitive mechanisms can (under 
certain circumstances) develop in the brain. In cultured PC12 cells, regulation of tyrosine hyodoxylase 
transcription has been shown to require HIF activation [26] and Pascual et al. (2001) reported that 
HIF1-α is selectively expressed in medullary regions during sustained hypoxia in rats, especially in 
glial cells [27]. Amifostine or its metabolites do not cross the blood brain barrier, but it has been 
advocated as a neuroprotective agent because it can influence the biochemistry of the cerebral vascular 
endothelium [28]. It is possible therefore, that the results we describe may be mediated by (indirect) 
central nervous system effects of amifostine (or HIF) rather than peripheral carotid body mechanisms, 
and this possibility warrants specific study. 
Our results refute the hypothesis that amifostine’s protective effect is via a reduction in basal 
metabolism. Our finding of increased hypoxic ventilatory response is consistent with its previously 
established upregulation of HIF. However, these findings raise a new dilemma that warrants 
explanation: upregulation of HIF is not consistent with a cellular protective effect since HIF activation 
is generally thought to be associated with promoting tumorigenic activity [29]. Our results therefore 
require fundamental re-analysis of the mode of action of amifostine. 
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